Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Autism: What Science Shows and What Remains Experimental
Transcript
- 0:00SPEAKER_01: Welcome to the Cyrena Cell podcast.
- 0:02SPEAKER_01: Right now, uh, all over the world, there are parents of children with autism spectrum disorder boarding international flights.
- 0:09SPEAKER_01: Yeah.
- 0:10SPEAKER_01: They are spending their life savings, you know, navigating this massive maze of conflicting internet forums and really risking it all on treatments that just aren't officially approved by standard medicine.
- 0:23SPEAKER_00: It's I mean, it's a profoundly vulnerable position for any family to be in.
- 0:27SPEAKER_01: Totally.
- 0:28SPEAKER_01: Because they're doing this out of just this relentless love for their kids, but they're stepping into a marketplace where the line between, you know, a real medical breakthrough and just a predatory sales pitch is incredibly blurry.
- 0:41SPEAKER_00: Trevor Burrus, Jr.: Right.
- 0:41SPEAKER_00: And when you're dealing with a neurodevelopmental condition that fundamentally alters how your child interacts with the world, the desire for a solution is just overwhelming.
- 0:49SPEAKER_00: But you know, that desperation is exactly what makes the distinction between proven science and experimental hope so vital.
- 0:56SPEAKER_01: Aaron Powell, which is really the core mission of our deep dive today.
- 0:58SPEAKER_01: We're exploring stem cell therapy for autism spectrum disorder, or ASD.
- 1:03SPEAKER_01: We're going to look at what the science actually shows, how the biology is uh supposed to work, and what remains strictly experimental.
- 1:10SPEAKER_00: Exactly.
- 1:10SPEAKER_01: And to ground this whole conversation, we are looking at the clinical philosophies and patient guides from Cyrona Cell, which is a doctor-led stem cell therapy and regenerative medicine center.
- 1:21SPEAKER_01: And they're based in Kuala Lumpur, Malaysia.
- 1:24SPEAKER_00: Right.
- 1:24SPEAKER_00: And having that specific baseline is critical because Kuala Lumpur has really become a major hub for medical tourism.
- 1:32SPEAKER_01: Oh, for sure.
- 1:33SPEAKER_00: And a clinic like this serves not just local patients, but this vast international service area.
- 1:39SPEAKER_00: I mean, they have many traveling from Australia, the Middle East, and beyond.
- 1:43SPEAKER_01: Wow.
- 1:44SPEAKER_00: So examining how a legitimate medically supervised center actually operates, well, it gives us a lens to evaluate everything else out there.
- 1:53SPEAKER_00: Aaron Powell Yeah.
- 1:53SPEAKER_01: And if you're a parent listening for this, you're probably just exhausted by the extreme opinions, right?
- 1:57SPEAKER_01: Oh, absolutely.
- 1:58SPEAKER_01: Like one side of the internet tells you stem cells are this magic cure, and then the other side tells you it's all a total scam.
- 2:03SPEAKER_01: So our goal today is to arm you with the actual biological facts so you can navigate this space safely.
- 2:09SPEAKER_00: Aaron Powell And safety really starts with knowing what the standard of care should look like before you even, you know, look at the treatment itself.
- 2:16SPEAKER_01: Aaron Powell Yeah.
- 2:16SPEAKER_01: So let's start right there with the benchmark for safe practice.
- 2:20SPEAKER_01: Because the name itself, Serona Cell, actually caught my eye.
- 2:24SPEAKER_00: Oh, really?
- 2:24SPEAKER_01: Yeah.
- 2:24SPEAKER_01: Serona is a Celtic goddess associated with health and specifically protection.
- 2:31SPEAKER_01: And that feels like a very intentional branding choice in an industry that's kind of infamous for shouting about like miracle cures.
- 2:39SPEAKER_00: It's very intentional.
- 2:40SPEAKER_00: And it highlights a massive red flag you should look out for in regenerative medicine.
- 2:44SPEAKER_00: Aaron Powell Okay.
- 2:45SPEAKER_01: What's that?
- 2:45SPEAKER_00: Aaron Ross Powell If a clinic is promising a quick fix or you know guaranteed results for a complex condition like autism, you should just walk away immediately.
- 2:53SPEAKER_01: Aaron Powell Right.
- 2:53SPEAKER_01: Just run.
- 2:54SPEAKER_00: Exactly.
- 2:55SPEAKER_00: Legitimate centers focus on protection, structured care, and incredibly strict ethical boundaries regarding the biological materials they use.
- 3:04SPEAKER_01: Aaron Powell Well, let's let's break down those biological materials because I feel like this is where a lot of the confusion happens.
- 3:10SPEAKER_00: Oh, absolutely.
- 3:11SPEAKER_00: It's a minefield.
- 3:12SPEAKER_01: Right.
- 3:12SPEAKER_01: Like when people hear stem cells, they immediately think of those massive controversies from the early 2000s.
- 3:17SPEAKER_00: Right, the embryonic debate.
- 3:19SPEAKER_01: Exactly.
- 3:20SPEAKER_01: But the cells being used in these modern ethical protocols are very different.
- 3:26SPEAKER_01: They use ethically sourced umbilical cord-derived cells, specifically from healthy, full-term deliveries where the donor has explicitly consented.
- 3:36SPEAKER_00: And that is a crucial distinction.
- 3:38SPEAKER_00: We're talking about Wharton's jelly mesenchymal stem cells, or WJMSCs for short.
- 3:43SPEAKER_01: Okay.
- 3:44SPEAKER_00: These are found in the tissue of the umbilical cord.
- 3:47SPEAKER_00: And, you know, just as importantly, we need to clarify what is strictly not being used.
- 3:51SPEAKER_01: Right, what's off the table.
- 3:52SPEAKER_00: Exactly.
- 3:53SPEAKER_00: Ethical clinics strictly avoid embryonic stem cells and experimental pluripotent stem cells.
- 3:58SPEAKER_01: Okay, I want to pause there because I hear those terms thrown around constantly.
- 4:02SPEAKER_01: Why is the line drawn so firmly against pluripotent cells here?
- 4:06SPEAKER_01: I mean, if pluripotent means the cell can turn into literally any type of tissue in the body, doesn't that make it like the ultimate healing tool?
- 4:15SPEAKER_00: Well, in a highly controlled laboratory setting for research, yes, they are incredible tools.
- 4:20SPEAKER_00: Okay.
- 4:21SPEAKER_00: But in a human patient, that limitless potential is exactly what makes them so dangerous.
- 4:26SPEAKER_01: Wait, really?
- 4:27SPEAKER_01: How so?
- 4:28SPEAKER_00: Well, pluripotent cells want to build an entirely new human being.
- 4:32SPEAKER_01: Oh, wow.
- 4:33SPEAKER_00: Yeah.
- 4:33SPEAKER_00: So if you inject them into a patient without the ability to perfectly control their behavior, they don't know when to stop growing.
- 4:40SPEAKER_01: Oh, jeez.
- 4:41SPEAKER_00: They can form what are called teratomas, which are basically tumors made of mixed tissues.
- 4:45SPEAKER_01: That is terrifying.
- 4:47SPEAKER_00: It is.
- 4:47SPEAKER_00: And that's exactly why clinical applications rely on misenchymal stem cells like the WJMSCs we mentioned.
- 4:53SPEAKER_01: Okay.
- 4:54SPEAKER_00: They are adult type stem cells.
- 4:56SPEAKER_00: Their potential is much more restricted.
- 4:58SPEAKER_00: They can't turn into just anything, which makes their safety profile significantly higher for these therapies.
- 5:03SPEAKER_01: Makes sense.
- 5:04SPEAKER_00: Furthermore, a top-tier clinic will specify that they use early passage cells.
- 5:08SPEAKER_01: Yeah, I actually saw that term early passage in the documentation.
- 5:12SPEAKER_01: What does that actually mean for the patient?
- 5:14SPEAKER_00: So think of a photocopier.
- 5:16SPEAKER_01: Okay.
- 5:16SPEAKER_00: The first time you copy a document, the image is perfectly crisp, right?
- 5:20SPEAKER_01: Yeah, nice and clear.
- 5:22SPEAKER_00: But you take that copy and copy it again and do that 50 times, the final image is degraded, it's blurry and full of artifacts.
- 5:29SPEAKER_01: Right, you can barely read it.
- 5:31SPEAKER_00: Exactly.
- 5:32SPEAKER_00: Well, cells in a lab divide in a very similar way.
- 5:35SPEAKER_00: Passage refers to how many times the cells have been expanded or multiplied in the petri dish.
- 5:40SPEAKER_01: Oh, I see.
- 5:40SPEAKER_01: So early passage means you're getting the crisp original copies.
- 5:44SPEAKER_00: Precisely.
- 5:45SPEAKER_00: They haven't been replicated to the point of exhaustion.
- 5:47SPEAKER_01: Okay.
- 5:48SPEAKER_00: They're younger, more robust, and they haven't accumulated the genetic mutations that you know occur when cells are forced to divide too many times in a lab environment?
- 5:58SPEAKER_01: Aaron Powell Which naturally brings up the lab environment itself, because getting a crisp copy doesn't matter if the photocopy are sitting in a swamp, right?
- 6:05SPEAKER_01: Exactly.
- 6:05SPEAKER_01: We see acronyms in the guides like CGMP, ISO 9001, and BSL2 laboratory standards.
- 6:13SPEAKER_01: Right.
- 6:13SPEAKER_01: To a lot of people, that's just alphabet soup.
- 6:16SPEAKER_01: Why should a family who is traveling for treatment care about these specific acronyms?
- 6:21SPEAKER_00: Because live cells are highly sensitive biological material.
- 6:25SPEAKER_00: Let's take BSL2, which stands for Biosafety Level 2.
- 6:28SPEAKER_01: Okay.
- 6:29SPEAKER_00: It means the lab has advanced air filtration, strict containment protocols, and dedicated sterilization processes.
- 6:36SPEAKER_01: Wow, so it's intense.
- 6:37SPEAKER_00: Very.
- 6:38SPEAKER_00: And then CGMP stands for current good manufacturing practice, which ensures every single batch is produced with consistent quality and tested for viability.
- 6:47SPEAKER_01: Viability meaning.
- 6:48SPEAKER_00: Meaning the cells are actually alive.
- 6:50SPEAKER_01: Right.
- 6:50SPEAKER_01: Kind of important.
- 6:51SPEAKER_00: Yeah, very.
- 6:52SPEAKER_00: Because if a clinic is not operating at these standards, I mean a single stray bacterium in the air vent could contaminate the batch.
- 6:59SPEAKER_01: Oh man.
- 6:59SPEAKER_00: Meaning you'd be injecting dangerous pathogens into a child.
- 7:02SPEAKER_01: Aaron Powell Okay, that completely shifts my perspective.
- 7:04SPEAKER_01: I always pictured the risk of stem cells as just, you know, maybe it won't work.
- 7:07SPEAKER_00: Right.
- 7:08SPEAKER_00: A lot of people do.
- 7:09SPEAKER_01: I wasn't thinking about the literal manufacturing environment.
- 7:12SPEAKER_01: And this ties into how a responsible clinic uh views its own role, right?
- 7:16SPEAKER_01: Like Cyreno Cell positions their regenerative medicine as an adjunct treatment.
- 7:21SPEAKER_01: So it's sort of like a copilot.
- 7:22SPEAKER_01: They aren't telling you to fire your neurologists.
- 7:24SPEAKER_01: Trevor Burrus, Jr.
- 7:25SPEAKER_00: And they never ever should.
- 7:26SPEAKER_00: Treating autism requires a massive multidisciplinary effort.
- 7:30SPEAKER_00: Trevor Burrus, Jr.
- 7:31SPEAKER_01: Right.
- 7:31SPEAKER_00: A legitimate regenerative clinic acts more like a highly specialized strike team.
- 7:36SPEAKER_01: Aaron Powell I like that analogy.
- 7:38SPEAKER_00: Aaron Powell Yeah, they're brought in to execute a specific biological intervention, but they are constantly communicating with the ground commander.
- 7:45SPEAKER_01: Aaron Powell Which would be the patient's primary neurologist.
- 7:47SPEAKER_00: Trevor Burrus Exactly.
- 7:48SPEAKER_00: They're neurologist, they're behavioral therapist, they're pediatrician.
- 7:51SPEAKER_01: Aaron Powell And part of being a responsible strike team is knowing when to abort the mission, right?
- 7:55SPEAKER_01: Trevor Burrus Absolutely.
- 7:56SPEAKER_01: It seems like the hallmark of ethical regenerative medicine is a clinic's willingness to look at your medical files and simply say, no, we cannot help you.
- 8:05SPEAKER_00: Aaron Powell That is the ultimate test of integrity.
- 8:08SPEAKER_00: If a clinic accepts every single patient who walks to the door with a checkbook, they are selling a product, they are not practicing medicine.
- 8:13SPEAKER_00: Aaron Powell All right.
- 8:14SPEAKER_01: So we've established the guardrails.
- 8:16SPEAKER_01: We know we're talking about highly regulated early passage umbilical cord cells operating under strict ethical and safety standards.
- 8:23SPEAKER_01: Right.
- 8:24SPEAKER_01: Now we have to ask the million-dollar question: why autism?
- 8:28SPEAKER_00: Aaron Powell Ah, yes.
- 8:30SPEAKER_01: Like, how on earth could an umbilical cord cell change how a neurodevelopmental disorder operates?
- 8:36SPEAKER_00: Aaron Powell To answer that, we really have to rethink what autism spectrum disorder actually looks like inside the body.
- 8:43SPEAKER_00: Aaron Powell Okay.
- 8:44SPEAKER_00: Because for decades, the medical consensus viewed ASD strictly as a wiring issue.
- 8:48SPEAKER_01: Aaron Powell Right, like a behavioral or psychological condition rooted entirely in how the brain's neurons were structurally connected during early development.
- 8:56SPEAKER_00: Aaron Powell Exactly.
- 8:56SPEAKER_00: The assessment was always that the hardware was just built differently.
- 8:59SPEAKER_01: Right.
- 8:59SPEAKER_00: But modern science has uncovered a massive missing piece of the puzzle.
- 9:04SPEAKER_00: Which is systemic immune dysfunction and chronic brain inflammation.
- 9:07SPEAKER_01: Oh wow.
- 9:08SPEAKER_01: I want to dig into that because inflammation is such a buzzword.
- 9:11SPEAKER_00: It really is.
- 9:12SPEAKER_01: Like people hear it and think of a swollen ankle.
- 9:16SPEAKER_01: What does inflammation actually look like inside the brain of a child with ASD?
- 9:20SPEAKER_00: Well, inside the brain, you have a specific type of immune cell called microglia.
- 9:25SPEAKER_01: Microglia.
- 9:26SPEAKER_01: Okay.
- 9:26SPEAKER_00: Think of them as the brain security guards and maintenance workers.
- 9:30SPEAKER_01: Oh, God.
- 9:30SPEAKER_00: Usually they patrol the area, clear out debris, and just keep the environment healthy.
- 9:35SPEAKER_01: Right.
- 9:36SPEAKER_00: But in many individuals with ASD, these microglia are stuck in the on position.
- 9:41SPEAKER_01: Oh, so they're overactive.
- 9:43SPEAKER_00: Yes.
- 9:44SPEAKER_00: They become overzealous.
- 9:45SPEAKER_00: They constantly release inflammatory chemicals, creating this highly toxic, chaotic environment for the actual neurons.
- 9:53SPEAKER_00: The brain cells.
- 9:54SPEAKER_00: Right, the cells that are actually trying to communicate.
- 9:56SPEAKER_01: Yeah, I was trying to visualize this earlier and I kept thinking about an old AM radio.
- 10:00SPEAKER_00: Okay, I like where this is going.
- 10:01SPEAKER_01: Like the brain's neurons are trying to broadcast a really clear song, which is a child's natural ability to speak, focus, and interact.
- 10:10SPEAKER_01: Right.
- 10:10SPEAKER_01: But these overactive microglia are creating this massive electrical storm.
- 10:15SPEAKER_01: There is so much heavy static that the song is just completely drowned out.
- 10:19SPEAKER_00: That is a highly accurate way to look at it.
- 10:22SPEAKER_00: The underlying neurological pathways might be there, but the biological interference is just scrambling the signal.
- 10:27SPEAKER_01: Aaron Powell So how do our stem cells fix the radio?
- 10:30SPEAKER_01: Do they actually travel into the brain and become new neurons?
- 10:34SPEAKER_01: Because that honestly sounds like science fiction.
- 10:36SPEAKER_00: And that is actually the most common misconception about stem cell therapy.
- 10:39SPEAKER_00: Really?
- 10:40SPEAKER_00: Yeah.
- 10:40SPEAKER_00: People assume the stem cells are these microscopic construction workers physically replacing damaged tissue.
- 10:45SPEAKER_01: Right.
- 10:45SPEAKER_01: That's what I pictured.
- 10:46SPEAKER_00: Aaron Powell Well, while WGMSCs can differentiate into other cell types under certain conditions, that is not their primary mechanism of action here.
- 10:54SPEAKER_01: Okay, so what are they doing?
- 10:55SPEAKER_00: What they actually do is exert what we call a pericrine effect.
- 10:58SPEAKER_01: The pericrine effect.
- 10:59SPEAKER_01: Okay, break that down for me.
- 11:01SPEAKER_01: What are they doing if they aren't building new brain cells?
- 11:03SPEAKER_00: Aaron Ross Powell, they act more like biochemical managers.
- 11:06SPEAKER_01: Okay.
- 11:07SPEAKER_00: When WGMSCs are introduced into the body, they secrete a highly complex cocktail of anti-inflammatory proteins, growth factors, and these microscopic messenger vehicles called exosomes.
- 11:20SPEAKER_01: Exosomes.
- 11:20SPEAKER_00: So they're basically just They essentially flood the local environment with new chemical instructions.
- 11:26SPEAKER_01: I see.
- 11:27SPEAKER_01: So they're handing out memos to the overactive security guards.
- 11:31SPEAKER_00: Precisely.
- 11:31SPEAKER_00: They send signals to those hyperactive microglia, telling them to stand down.
- 11:36SPEAKER_01: Oh wow.
- 11:37SPEAKER_00: Right.
- 11:37SPEAKER_00: They tell them to stop releasing inflammatory chemicals and return to their normal maintenance duties.
- 11:42SPEAKER_01: That's amazing.
- 11:43SPEAKER_00: They literally tune out the static.
- 11:45SPEAKER_00: So by altering the systemic environment, calming the immune system, and reducing the inflammation, they allow the brain's existing neurons to finally communicate clearly.
- 11:55SPEAKER_01: That is absolutely fascinating.
- 11:57SPEAKER_01: They aren't rewriting the brain's hardware at all.
- 11:59SPEAKER_01: They're just cleaning up the environment so the hardware can actually function.
- 12:03SPEAKER_00: Exactly.
- 12:03SPEAKER_00: That is the underlying biological hypothesis of why this could be such a revolutionary approach.
- 12:08SPEAKER_01: But, and this is a massive butt, right?
- 12:11SPEAKER_01: A beautiful biological hypothesis does not automatically equal a safe, standardized medical treatment.
- 12:17SPEAKER_00: Correct.
- 12:18SPEAKER_01: We have to pivot from the theoretical science to the harsh reality of clinical application.
- 12:24SPEAKER_01: Let's look at the actual clinical trials.
- 12:26SPEAKER_00: And this is where we really must apply intense scientific rigor.
- 12:31SPEAKER_01: Totally.
- 12:31SPEAKER_01: So let's start with the good news, the encouraging data.
- 12:34SPEAKER_00: Right.
- 12:34SPEAKER_01: Small clinical trials involving children with autism have been completed, and the results have shown genuine promise.
- 12:40SPEAKER_00: Yes, they have.
- 12:41SPEAKER_01: Some children demonstrated measurable improvements in speech, in their ability to maintain focus, and in social interactions.
- 12:48SPEAKER_00: This was incredible.
- 12:49SPEAKER_01: Yeah.
- 12:50SPEAKER_01: And crucially, in these highly regulated trials, the reported side effects were generally mild and short term, like maybe temporary fatigue or slight fever.
- 12:59SPEAKER_00: And you know, for a family living with severe ASD, hearing that a child spoke a new word or was able to hold eye contact because the brain inflammation was reduced, I mean, that isn't just data.
- 13:10SPEAKER_00: That is a profound life-altering shift in their daily reality.
- 13:14SPEAKER_01: Exactly.
- 13:15SPEAKER_01: And that brings up the exact question every parent listening right now is probably shouting at their speakers.
- 13:20SPEAKER_01: Right.
- 13:21SPEAKER_01: If kids are seeing real improvements and the side effects are just a mild fever, why on earth isn't every pediatrician in the world prescribing this today?
- 13:29SPEAKER_00: It's the most logical question.
- 13:31SPEAKER_01: Like, why isn't this the immediate standard of care?
- 13:34SPEAKER_00: It is the natural question to ask.
- 13:36SPEAKER_00: But this is exactly where the speed of hope collides with the agonizingly slow pace of medical science.
- 13:42SPEAKER_00: Yeah.
- 13:43SPEAKER_00: Because despite the promising results, stem cell therapy for autism remains officially classified as an experimental treatment.
- 13:50SPEAKER_01: Still.
- 13:51SPEAKER_00: Still.
- 13:52SPEAKER_00: And doctors do not and legally cannot recommend experimental treatments as standard care.
- 13:58SPEAKER_01: But why?
- 13:58SPEAKER_01: I mean, if it works for some kids, why hold it back?
- 14:01SPEAKER_00: Because of that exact phrase, some kids.
- 14:04SPEAKER_00: The current clinical trials rely on very small groups of patients, and they observe those patients for a relatively short period of time.
- 14:11SPEAKER_01: Right.
- 14:11SPEAKER_01: Okay.
- 14:12SPEAKER_00: In science, if you treat 20 children and 15 show improvement over six months, well, you have found an exciting trend.
- 14:18SPEAKER_01: Yeah.
- 14:19SPEAKER_00: But you have absolutely not proven a universal safe medical fact.
- 14:22SPEAKER_01: Because autism isn't just one thing, right?
- 14:24SPEAKER_01: It's a massive spectrum with different genetic and environmental triggers.
- 14:30SPEAKER_00: Exactly.
- 14:31SPEAKER_00: What works beautifully for a child whose ASD is heavily driven by immune dysfunction might do absolutely nothing for a child whose ASD is driven by a specific genetic mutation.
- 14:41SPEAKER_01: Oh, that makes total sense.
- 14:42SPEAKER_00: Yeah, we simply do not have the massive phase three clinical trials involving thousands of diverse patients that are required to standardize a treatment.
- 14:51SPEAKER_01: Aaron Powell And the researchers themselves acknowledge this, right?
- 14:54SPEAKER_01: The clinical philosophy from our benchmark center explicitly lists the unanswered questions that the scientific community is still frantically trying to solve.
- 15:02SPEAKER_00: Yes, they do.
- 15:03SPEAKER_00: I mean, they still need to know.
- 15:05SPEAKER_00: Are umbilical cord-derived WJMSEs universally superior to cells derived from, say, bone marrow or fat tissue?
- 15:13SPEAKER_00: And what is the exact optimal dose for a 40-pound child versus an 80-pound teenager?
- 15:18SPEAKER_01: And what about the durability of the effect?
- 15:20SPEAKER_01: Because if the stem cells are just managers handing out memos to calm the inflammation, what happens when those sting cells eventually leave the body?
- 15:27SPEAKER_00: Exactly.
- 15:28SPEAKER_01: Do the overactive microaglia just wake back up and start causing static again?
- 15:32SPEAKER_00: That is one of the most critical unknowns in the field right now.
- 15:35SPEAKER_01: Really?
- 15:36SPEAKER_00: Yeah.
- 15:37SPEAKER_00: Do these children need repeated treatments every six months?
- 15:41SPEAKER_00: Every year.
- 15:42SPEAKER_00: Oh right.
- 15:43SPEAKER_00: And if they do, what is the cumulative effect of introducing massive amounts of donor biological material into a developing child's immune system over a decade?
- 15:53SPEAKER_01: Oh, I didn't even think about that.
- 15:54SPEAKER_00: Right.
- 15:55SPEAKER_00: Like, do we inadvertently trigger an autoimmune response five years down the line?
- 16:00SPEAKER_01: Those are incredibly heavy questions.
- 16:02SPEAKER_00: They are.
- 16:03SPEAKER_01: And until we have what, 10 or 20 years of robust peer-reviewed safety data, the medical community's hands are essentially tied.
- 16:11SPEAKER_01: They are bound by the oath to do no harm.
- 16:13SPEAKER_00: Aaron Powell Exactly.
- 16:14SPEAKER_00: Which means standardizing an experimental treatment prematurely is an ethical violation, no matter how promising the early data looks.
- 16:21SPEAKER_01: So what does this reality mean for the families navigating this today?
- 16:24SPEAKER_00: It's tough.
- 16:25SPEAKER_01: Aaron Ross Powell Because a mother watching her child struggle right now cannot wait 15 years for the final clinical trial data to be published.
- 16:32SPEAKER_00: No, she can't.
- 16:33SPEAKER_01: And that urgency pushes families out of the safe, regulated corridors of standard medicine and straight into the wild west of global medical tourism.
- 16:42SPEAKER_00: Aaron Powell And that landscape is incredibly fraught with danger.
- 16:46SPEAKER_00: You have highly ethical clinics trying to conduct careful documented research, operating right next door to unscrupulous actors who are perfectly happy to exploit a parent's desperation.
- 16:58SPEAKER_01: Aaron Powell Not to mention the financial devastation.
- 17:01SPEAKER_01: Because this is experimental, it is rarely, if ever, covered by insurance.
- 17:06SPEAKER_00: Right.
- 17:06SPEAKER_01: Families are draining their retirement accounts and taking out second mortgages to pay for these procedures out of pocket.
- 17:12SPEAKER_00: Which is why the need for self-advocacy is absolutely paramount.
- 17:16SPEAKER_00: If you are going to step into this experimental space, you have to protect yourself with information.
- 17:21SPEAKER_01: So let's talk about how to do that.
- 17:23SPEAKER_01: Say I'm a parent and I'm looking at a clinic's website right now.
- 17:25SPEAKER_01: What are the immediate questions I need to be asking?
- 17:28SPEAKER_00: First, demand transparency about their clinical trial status.
- 17:32SPEAKER_00: Is this center operating under an officially approved clinical framework recognized by their local medical authorities?
- 17:38SPEAKER_00: Or are they just a private business administering biological material with zero oversight?
- 17:44SPEAKER_01: Right.
- 17:45SPEAKER_01: And you should look at how they handle your current medical team.
- 17:47SPEAKER_00: Definitely.
- 17:48SPEAKER_01: If a clinic ever suggests that you should stop seeing your licensed neurologist or pull your child out of standard behavioral therapy to rely solely on their stem cells, run the other way.
- 17:58SPEAKER_00: Absolutely.
- 17:59SPEAKER_00: Run fast.
- 18:00SPEAKER_00: Furthermore, ask them about their patient tracking and follow-up protocols.
- 18:03SPEAKER_01: Why is that important?
- 18:04SPEAKER_00: Because an ethical clinic is obsessed with data.
- 18:08SPEAKER_00: They will want to track your child's progress and any potential side effects for months or years after the procedure.
- 18:14SPEAKER_01: Right.
- 18:14SPEAKER_00: If a clinic's involvement ends the moment the check clears and the IV is removed, they are not practicing medicine.
- 18:20SPEAKER_01: Speaking of the cave, the delivery method is another huge factor, isn't it?
- 18:24SPEAKER_00: It is.
- 18:25SPEAKER_01: Legitimate protocols for this specific application focus on minimally invasive delivery, usually intravenous infusions or highly targeted localized injections.
- 18:35SPEAKER_01: There should not be aggressive, open surgical procedures involved in standard WJMSC protocols for autism.
- 18:43SPEAKER_00: Never.
- 18:44SPEAKER_00: Ultimately, you need balanced guidance from licensed doctors who truly understand the complexities of autism spectrum disorder.
- 18:51SPEAKER_00: You need someone who will look you in the eye and give you the harsh facts without serving up false hope.
- 18:56SPEAKER_01: Yeah, the burden of proof right now is essentially on the patient, which is incredibly difficult.
- 19:01SPEAKER_00: Yes.
- 19:01SPEAKER_01: But the good news is that regenerative medicine is not stagnant.
- 19:05SPEAKER_01: It is one of the fastest growing fields in science right now.
- 19:07SPEAKER_00: Oh, without a doubt.
- 19:08SPEAKER_01: Study designs are becoming more sophisticated, patient tracking is improving globally, and the evidence base will get stronger over time.
- 19:15SPEAKER_00: It absolutely will.
- 19:16SPEAKER_00: But until that evidence is solidified into standard medical protocol, families must remain vigilant.
- 19:22SPEAKER_00: The potential is real, but so are the risks of the unknown.
- 19:26SPEAKER_01: It's a delicate tightrope between profound hope and cold hard facts.
- 19:31SPEAKER_00: Perfectly sad.
- 19:32SPEAKER_01: So to wrap up our deep dive today, the science clearly shows that stem cell therapy, particularly using umbilical cord-derived WJMSCs, offers a fascinating biological mechanism.
- 19:44SPEAKER_00: By leveraging the pericrine effect, these cells have the potential to tune out the radiostatic-reducing brain inflammation and allowing for better neurological communication in some individuals with ASD.
- 19:57SPEAKER_01: But the reality check remains.
- 19:58SPEAKER_01: Yeah.
- 19:59SPEAKER_01: It is strictly experimental.
- 20:01SPEAKER_00: Yeah.
- 20:01SPEAKER_01: The medical community requires vastly more long-term data regarding safety, exact dosing, and the longevity of the benefits before this can ever be considered standard care.
- 20:12SPEAKER_01: Trevor Burrus, Jr.
- 20:12SPEAKER_00: Right.
- 20:13SPEAKER_00: But before we sign off, I want to leave you with a final thought to mull over.
- 20:16SPEAKER_01: Okay.
- 20:16SPEAKER_00: Something that builds on what we've learned today about these incredible cells.
- 20:20SPEAKER_00: We talked extensively about how WJMSEs don't become brain cells, they act as managers.
- 20:25SPEAKER_00: Trevor Burrus, Jr.
- 20:25SPEAKER_01: Right, the biochemical managers.
- 20:26SPEAKER_00: They use exosomes and proteins to communicate with the brain's overactive immune system, telling it to calm down.
- 20:33SPEAKER_00: The chemical memos.
- 20:34SPEAKER_00: Exactly, the chemical memos.
- 20:36SPEAKER_00: But what if we eventually learn to read those memos?
- 20:38SPEAKER_01: Oh, interesting.
- 20:39SPEAKER_00: What if scientists decode the exact chemical language these stem cells use to communicate?
- 20:44SPEAKER_01: Aaron Powell Yeah, that raises a fascinating possibility.
- 20:46SPEAKER_01: Aaron Powell Right.
- 20:47SPEAKER_01: Because if we understand the language, maybe the future of regenerative medicine doesn't require donor stem cells at all.
- 20:53SPEAKER_01: Right.
- 20:54SPEAKER_01: What if instead of introducing foreign cells to calm the inflammation temporarily, we could just synthesize that specific chemical language.
- 21:02SPEAKER_01: Oh wow.
- 21:03SPEAKER_01: We could deliver a targeted message that teaches the child's own native brain cells how to repair and regulate themselves permanently.
- 21:11SPEAKER_00: Now, that is a profound shift in thinking.
- 21:14SPEAKER_00: Moving away from a temporary biological intervention and toward a permanent self-sustaining biological education.
- 21:22SPEAKER_01: Yeah, if we can eventually give the brain its own sound mixing board, that uncharted map of neurodevelopment might finally lead to a clear, predictable destination.
- 21:31SPEAKER_00: It is arguably the most compelling frontier in modern science.
- 21:34SPEAKER_01: It really is.
- 21:35SPEAKER_01: Thank you for joining us on this deep dive into the fascinating, evolving world of regenerative medicine.
- 21:40SPEAKER_01: Keep asking questions, keep demanding the facts, and never stop looking for the evidence.